Please ensure Javascript is enabled for purposes of website accessibility

3 Great Stocks With Better Growth Prospects Than Tesla to Buy

By Keith Speights – Sep 16, 2020 at 6:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They're all innovative disruptors, but these three stocks could outperform Tesla over the next decade.

How much higher can Tesla (TSLA 1.19%) go? The answer depends on the answer to another question: How much can Tesla grow?

To be sure, the company has to deliver a tremendous amount of growth to justify its current valuation. Tesla bulls think it will do just that given the potential of the company's self-driving car technology and its energy business, as well as its opportunities from the rising adoption of electric vehicles.

Maybe Tesla will generate sizzling growth for years to come. However, I think there are three great stocks to buy right now that have better growth prospects than Tesla. 

Business person holding a bright light in their palm with several upward-trending lines extending from it.

Image source: Getty Images.

1. Guardant Health

Guardant Health (GH -5.01%) stands out as a pioneer in the liquid biopsy market. What is a liquid biopsy? It's a way of detecting the presence of cancer by finding fragments of DNA broken off from tumor cells in an individual's blood.

The potential market for liquid biopsies is enormous. Guardant Health estimates the addressable annual market in the U.S. alone tops $50 billion. This huge opportunity includes early stage cancer detection, recurrence monitoring, and use of liquid biopsy products as companion diagnostics for cancer drugs.

While Guardant Health isn't the only company targeting the big liquid biopsy market, it has less intense competition than Tesla does in its market. Guardant has also built an early lead. It already has two liquid biopsy products on the market. The company's Guardant360 product is used by more than 7,000 oncologists and over 60 drugmakers. It was also the first comprehensive liquid biopsy to win Food and Drug Administration approval.

Tesla's trailing-12-month sales have soared nearly 140% over the last three years, but Guardant Health's two products have fueled sales growth twice that level in less time. The company's Lunar liquid biopsy tests, which are in clinical testing, should boost its growth significantly within the next few years.

2. Innovative Industrial Properties

You might be surprised that a real estate investment trust (REIT) could have better growth prospects than sizzling-hot Tesla -- but Innovative Industrial Properties (IIPR 0.22%) isn't just any REIT. The company ranks as the leading provider of real estate capital to the U.S. medical cannabis market.

IIP currently owns 62 properties in 16 states, all of which are leased to medical cannabis operators. By comparison, the company had only 46 properties at the end of 2019. IIP's steady property acquisitions have driven its trailing-12-month revenue a whopping 1,600% higher over the last three years.  

It shouldn't be overly difficult for IIP to keep its growth streak going. The company has ample opportunities to expand in the states where it currently operates, as well as the other 17 states where medical cannabis is already legal. Even more states are voting in November to potentially legalize cannabis

While Tesla has trounced IIP in terms of stock performance so far this year, it's a different story over the last three years. IIP also provides another goodie for investors: its dividend. As an REIT, the company must return at least 90% of taxable income to shareholders in the form of dividends. IIP's dividend yield currently stands at close to 3.5%.

3. MongoDB

MongoDB (MDB -3.99%) is another growth stock that has outperformed Tesla over the last three years and could extend its dominance over the next decade. The company's cloud database platform has proven to be especially popular with customers.

At first glance, MongoDB might seem to have a daunting challenge competing against database heavyweights such as Microsoft and Oracle. However, unlike these large rivals, MongoDB's database was built from the ground up to handle the kinds of unstructured data that's prevalent today. It was also designed to run anywhere, including the cloud.

The company's primary growth driver is its Atlas fully managed database service. With Atlas, customers can quickly scale up databases in the cloud and expand as needed with minimal hassle. Both small and big organizations have flocked to MongoDB's cloud platform, including technology leaders such as Adobe and Google

MongoDB CEO Dev Ittycheria said in the company's second-quarter conference call earlier this month that MongoDB will "continue disrupting one of the largest markets in software." This sustained disruption should enable MongoDB to keep its remarkable growth story going for a long time to come.

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Keith Speights owns shares of Alphabet (A shares), Guardant Health, Innovative Industrial Properties, Microsoft, and MongoDB. The Motley Fool owns shares of and recommends Adobe Systems, Alphabet (A shares), Alphabet (C shares), Guardant Health, Innovative Industrial Properties, Microsoft, MongoDB, and Tesla and recommends the following options: long January 2021 $85 calls on Microsoft and short January 2021 $115 calls on Microsoft. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.